DRKS00025984已完成不适用
Clinical study to investigate the safe and effective use of Stethoglove® by health care professionals under real-life conditions
Stethoglove GmbH0 个研究点目标入组 54 人开始时间: 2021年11月18日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 100 Years（—）
- 性别
- All
入选标准
- •Adult male and female patients (=18 years) elected for cardiac surgery
- •- Ability to understand the purpose and risks of the clinical study and to provide signed and dated informed consent
排除标准
- •- Known allergy or contact sensitization against the Stethoglove® material (thermoplastic urethane, TPU)
- •- Patients with known HIV, Hepatitis B or C infections
- •- Legal incapacity or limited legal capacity
- •- Participation in an interventional clinical trial within 30 days prior to enrollment
- •- Employees of the sponsor or patients who are employees or relatives of the users
- •- Patients committed to an institution by virtue of an order issued either by the judicial or the administrative authorities
研究者
相似试验
进行中（未招募）
1 期
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immundeficiency Diseases (PID)MedDRA version: 9.1 Level: LLT Classification code 10064859 Term: Primary immunodeficiency syndromeEUCTR2007-002611-27-GBOctapharma AG5
进行中（未招募）
1 期
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immunodeficiency Diseases (PID)MedDRA version: 9.1Level: LLTClassification code 10064859Term: Primary immunodeficiency syndromeEUCTR2007-002611-27-FROctapharma AG5
进行中（未招募）
不适用
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immundeficiency Diseases (PID)MedDRA version: 9.1Level: LLTClassification code 10064859Term: Primary immunodeficiency syndromeEUCTR2007-002611-27-DEOctapharma AG45
已完成
不适用
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in primary immunodeficiency diseasesPrimary immunodeficiency diseases (PID)Haematological DisordersOther immunodeficienciesISRCTN63491981Octapharma AG (Switzerland)45
已完成
2 期
Role of GastriCare in Digestive wellbeingCTRI/2018/04/013249The Himalaya Drug Company60